Picton Mahoney Asset Management Buys 118,703 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Picton Mahoney Asset Management raised its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 24.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 607,090 shares of the company’s stock after acquiring an additional 118,703 shares during the quarter. Picton Mahoney Asset Management owned approximately 0.16% of GoodRx worth $4,736,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rubric Capital Management LP bought a new stake in GoodRx during the 4th quarter worth approximately $39,348,000. Rip Road Capital Partners LP lifted its position in GoodRx by 25.8% during the 4th quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock worth $11,814,000 after buying an additional 361,294 shares in the last quarter. GSA Capital Partners LLP bought a new stake in GoodRx during the 1st quarter worth about $1,638,000. Mirae Asset Global Investments Co. Ltd. increased its position in GoodRx by 61.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock valued at $1,289,000 after acquiring an additional 68,835 shares in the last quarter. Finally, Mckinley Capital Management LLC bought a new position in shares of GoodRx in the first quarter worth about $1,280,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on GDRX. UBS Group lowered their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Barclays lifted their price objective on GoodRx from $9.00 to $10.00 and gave the stock an “overweight” rating in a research report on Monday, May 20th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a research report on Friday, August 9th. Finally, Morgan Stanley increased their price objective on shares of GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, GoodRx presently has an average rating of “Moderate Buy” and an average price target of $9.36.

GoodRx Stock Down 3.8 %

Shares of NASDAQ:GDRX traded down $0.31 during midday trading on Friday, reaching $7.90. 3,411,475 shares of the company were exchanged, compared to its average volume of 1,932,395. The firm has a market cap of $2.96 billion, a PE ratio of -790.00, a P/E/G ratio of 3.74 and a beta of 1.39. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26. The stock has a fifty day simple moving average of $8.03 and a two-hundred day simple moving average of $7.52.

GoodRx (NASDAQ:GDRX) last released its earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business had revenue of $200.60 million during the quarter, compared to the consensus estimate of $200.47 million. During the same period last year, the business posted $0.02 EPS. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.15 earnings per share for the current year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.